IIT Hyderabad researchers develop oral tablets for treating leishmaniasis, fungal infections

Image
ANI General News
Last Updated : Aug 23 2019 | 2:45 AM IST

With an aim to treat fungal infections and leishmaniasis (kala-azar and black fever) prevalent in the country, researchers at Indian Institute of Technology (IIT) Hyderabad have developed a method to produce controlled-release oral tablets.

The tablets were found to release the drug Amphotericin B in a sustained and controlled manner over a period of 10 days, read a statement from the institution.

"Amphotericin B (AmB) is the drug of choice for progressive and potentially life-threatening fungal infections of the abdomen and heart valves, fungal pneumonia, and leishmaniasis, a neglected tropical disease. It is used to treat Kala Azar or black fever, a dangerous and often fatal form of Leishmaniasis, common among the economically underprivileged sections in states such as Bihar, Jharkhand, West Bengal and Uttar Pradesh," the statement read.

It added that the development of oral, controlled-release tablets for fatal fungal infections and leishmaniasis, could help in better management of the disease burden in the country.

The development of cures for dangerous fungal diseases and leishmania has been challenging, IIT Hyderabad stated.

Professor Brahmchari who first used an antimony compound for treating kala-azar in the 1920s was even nominated for the Nobel Prize in 1929.

.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 23 2019 | 2:33 AM IST

Next Story